Denali Therapeutics (NASDAQ:DNLI) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Denali Therapeutics (NASDAQ:DNLI) from a buy rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. “

A number of other brokerages have also recently commented on DNLI. ValuEngine upgraded WPP from a sell rating to a hold rating in a research note on Wednesday, June 19th. TheStreet upgraded SUMMIT THERAPEU/S from a d rating to a c- rating in a research note on Thursday, June 13th. Finally, HC Wainwright reiterated a buy rating on shares of ACASTI PHARM-TS in a research note on Wednesday, June 26th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $25.50.



Shares of DNLI stock traded up $0.37 during trading hours on Tuesday, reaching $21.17. The company’s stock had a trading volume of 1,093 shares, compared to its average volume of 340,353. The company’s 50 day moving average is $19.94. The firm has a market capitalization of $2.00 billion, a P/E ratio of -53.58 and a beta of 2.12. Denali Therapeutics has a fifty-two week low of $12.32 and a fifty-two week high of $28.86. The company has a quick ratio of 11.55, a current ratio of 11.55 and a debt-to-equity ratio of 0.14.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.01). The business had revenue of $4.21 million during the quarter, compared to analyst estimates of $12.88 million. Denali Therapeutics had a negative net margin of 38.84% and a negative return on equity of 10.23%. On average, research analysts expect that Denali Therapeutics will post -1.54 EPS for the current year.

In related news, COO Alexander O. Schuth sold 7,500 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $20.28, for a total transaction of $152,100.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Ryan J. Watts sold 18,334 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $24.20, for a total value of $443,682.80. The disclosure for this sale can be found here. Insiders sold a total of 130,000 shares of company stock valued at $2,715,736 over the last quarter. 21.20% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in DNLI. BlackRock Inc. raised its position in Denali Therapeutics by 38.3% during the 4th quarter. BlackRock Inc. now owns 4,572,695 shares of the company’s stock worth $94,469,000 after purchasing an additional 1,265,645 shares during the last quarter. Wasatch Advisors Inc. raised its position in Denali Therapeutics by 1,702.4% during the 1st quarter. Wasatch Advisors Inc. now owns 820,904 shares of the company’s stock worth $19,061,000 after purchasing an additional 775,358 shares during the last quarter. Baillie Gifford & Co. raised its position in Denali Therapeutics by 0.6% during the 1st quarter. Baillie Gifford & Co. now owns 6,262,226 shares of the company’s stock worth $145,408,000 after purchasing an additional 34,502 shares during the last quarter. New York State Common Retirement Fund raised its position in Denali Therapeutics by 114.9% during the 4th quarter. New York State Common Retirement Fund now owns 44,700 shares of the company’s stock worth $924,000 after purchasing an additional 23,900 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Denali Therapeutics by 11.7% during the 4th quarter. Bank of New York Mellon Corp now owns 227,505 shares of the company’s stock worth $4,700,000 after purchasing an additional 23,809 shares during the last quarter. 71.69% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: Beige Book

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.